Cardiol Therapeutics (CRDL) Accounts Payables (2020 - 2026)

Cardiol Therapeutics' Accounts Payables history runs 7 years deep, the most recent figure standing at $2.5 million for Q1 2026.

• Quarterly Accounts Payables fell 53.63% year-over-year to $2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 million (down 53.63% YoY) and the FY2025 annual result came in at $2.5 million, down 50.05% from the prior year.
• Accounts Payables was $2.5 million for Q1 2026 at Cardiol Therapeutics, roughly flat from $2.5 million in the prior quarter.
• Across five years, Accounts Payables topped out at $6.9 million in Q2 2024 and bottomed at $2.4 million in Q3 2025.
• A 5-year average of $5.1 million and a median of $5.4 million in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2022 — Accounts Payables jumped 193.3% — and 2026, when it plunged 53.63%.
• Cardiol Therapeutics' Accounts Payables stood at $6.9 million in 2022, then fell by 14.1% to $5.9 million in 2023, then dropped by 15.45% to $5.0 million in 2024, then slumped by 50.05% to $2.5 million in 2025, then slipped by 0.04% to $2.5 million in 2026.
• Business Quant data shows CRDL's Accounts Payables at $2.5 million in Q1 2026, $2.5 million in Q4 2025, and $2.4 million in Q3 2025.